MedinCell S.A (MEB F) stock market data APIs
€26.8808
-0.11(-0.4%)
as of January 16, 2026
Try our APIs with
free plan!
MedinCell S.A Financial Data Overview
Price chart is built with
Anychart
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
Prev. Close
26.8808
Open
26.7738
High
27.0136
Low
26.6138
52 wk Range
12.06-37.82
Market Cap
902 M
Shares Outstanding
33 346 K
Revenue
32 439 K
Beta
1.047
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 32 439 K
- EBITDA: -9 569 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
MONTPELLIER, France, August 02, 2023--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, ...
MedinCell has Received the Last Tranche of €10m from the European Investment Bank (EIB) Loan
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The drawdown of this last tranche of a 40 million euros total loan signed with the EIB in November 2022...
MedinCell Announces the Availability of Its 2022-23 Universal Registration Document Including the Annual Financial Report
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The 2022-23 Universal Registration Document (URD) filed with the French market authority (Autorités de...
Half-Year Liquidity Contract Statement for MEDINCELL
PARIS, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
